5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 56 points (-0.3%) at 15,939 as of Wednesday, Feb. 12, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,598 issues advancing vs. 1,323 declining with 154 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 1.2%. Top gainers within the industry include Seattle Genetics ( SGEN), up 12.6%, Incyte ( INCY), up 4.4%, Jazz Pharmaceuticals ( JAZZ), up 4.3%, Biomarin Pharmaceutical ( BMRN), up 3.3% and GlaxoSmithKline ( GSK), up 1.1%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Actavis ( ACT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Actavis is down $1.40 (-0.7%) to $189.85 on light volume. Thus far, 479,430 shares of Actavis exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $189.21-$193.21 after having opened the day at $192.27 as compared to the previous trading day's close of $191.25.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $32.9 billion and is part of the health care sector. Shares are up 13.8% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $6.77 (-2.1%) to $319.75 on heavy volume. Thus far, 889,853 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 803,700 shares. The stock has ranged in price between $319.00-$331.64 after having opened the day at $326.00 as compared to the previous trading day's close of $326.52.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.6 billion and is part of the health care sector. Shares are up 18.6% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Eli Lilly and Company ( LLY) is down $0.79 (-1.5%) to $53.23 on average volume. Thus far, 2.3 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.1 million shares. The stock has ranged in price between $53.14-$54.15 after having opened the day at $54.15 as compared to the previous trading day's close of $54.02.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $60.8 billion and is part of the health care sector. Shares are up 6.9% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. Among the primary strengths of the company is its expanding profit margins over time. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.67 (-1.2%) to $55.03 on average volume. Thus far, 5.2 million shares of Merck exchanged hands as compared to its average daily volume of 12.8 million shares. The stock has ranged in price between $54.86-$55.69 after having opened the day at $55.44 as compared to the previous trading day's close of $55.70.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $160.4 billion and is part of the health care sector. Shares are up 11.3% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. Among the primary strengths of the company is its solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.22 (-0.7%) to $31.66 on light volume. Thus far, 8.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 26.2 million shares. The stock has ranged in price between $31.63-$32.00 after having opened the day at $31.87 as compared to the previous trading day's close of $31.88.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $204.0 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

Icahn Bets on Allergan's Brett Saunders in Post-Pfizer Era

What Bill Ackman's Voice Could Mean for the Valeant Board Room

What Bill Ackman's Voice Could Mean for the Valeant Board Room

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Federal Reserve to Reassess Global Risks in Minutes on Wednesday